
Number of publications published per year by Machida, Keigo. (Source : PubMed)

Distribution of publications types for Machida, Keigo. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)
NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.
Lipids Health Dis
2010;9

Hepatitis C virus causes uncoupling of mitotic checkpoint and chromosomal polyploidy through the Rb pathway.
J. Virol.
2009;83;23

Ethanol augments RANTES/CCL5 expression in rat liver sinusoidal endothelial cells and human endothelial cells via activation of NF-kappa B, HIF-1 alpha, and AP-1.
J. Immunol.
2009;183;9

Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins.
Gastroenterology
2009;137;1


"Second hit" models of alcoholic liver disease.
Semin. Liver Dis.
2009;29;2
SYNCRIP (synaptotagmin-binding, cytoplasmic RNA-interacting protein) is a host factor involved in hepatitis C virus RNA replication.
Virology
2009;386;2

Hepatitis C virus infection of T cells inhibits proliferation and enhances fas-mediated apoptosis by down-regulating the expression of CD44 splicing variant 6.
J. Infect. Dis.
2009;199;5

Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog.
Proc. Natl. Acad. Sci. U.S.A.
2009;106;5

Higher susceptibility of NOG mice to xenotransplanted tumors.
J Toxicol Sci
2009;34;1

[Pulmonary eosinophilia caused by visceral larva due to Ascaris suum]
Nippon Naika Gakkai Zasshi
2009;98;1
[ See timeline ] [ See all publications ]
means that Machida, Keigo has 12 papers cited a least 12 times - methodology
Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, Los Angeles, California 90033, USA.
Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.